NWCI: AI 评分 58/100 — AI 分析 (4月 2026)

NewCardio, Inc. focuses on developing and commercializing non-invasive cardiac diagnostic solutions. Their technology platform offers real-time analysis of heart's electrical activity and cardiac safety assessment of drugs.

Key Facts: Price: $0.00 AI Score: 58/100 Sector: Healthcare

公司概况

概要：

NewCardio, Inc. pioneers non-invasive cardiac diagnostics with its proprietary software platform, offering real-time 3D analysis of heart activity and cardiac safety assessments, positioning it as a key player in the evolving cardiovascular disease management landscape despite its micro-cap status.

NWCI是做什么的？

Founded in 2004 and based in Branchburg, New Jersey, NewCardio, Inc. is a cardiac diagnostic and services company dedicated to the research, development, and commercialization of proprietary software platform technology solutions. The company addresses the critical need for non-invasive diagnosis and monitoring of cardiovascular disease (CVD) and cardiac safety assessment of drugs under development. NewCardio's core technology platform provides real-time and 3-D analysis of the heart's electrical activity, utilizing standard 12-lead electrocardiogram (ECG) electrodes to detect activity at the body surface. Their developing product pipeline includes QTinno, an automated cardiac safety solution designed to replace manual methodologies with algorithms for ECG analysis and reporting. Another key product is CardioBip, a mobile ECG transtelephonic system that comprises a mobile ECG recording and transmitting device, coupled with web-enabled software for data processing and analysis. Additionally, NewCardio is developing my3KG, a software application aimed at assessing cardiac electrical activity in both time and space, further expanding its diagnostic capabilities. NewCardio aims to improve the accuracy and efficiency of cardiac diagnostics, contributing to better patient outcomes in the management of cardiovascular diseases.

NWCI的投资论点是什么？

Investing in NewCardio, Inc. presents a speculative opportunity within the cardiac diagnostics sector. The company's focus on innovative, non-invasive solutions for CVD diagnosis and cardiac safety assessment positions it for potential growth, particularly with products like QTinno and CardioBip. Key value drivers include successful commercialization of these technologies and strategic partnerships within the pharmaceutical industry for cardiac safety assessments. While the company's negative P/E ratio and significant negative profit margin of -4466.2% indicate financial challenges, successful development and adoption of their technology could drive significant revenue growth. Investors should closely monitor the company's progress in securing regulatory approvals and establishing market presence. The high beta of -120.60 suggests extreme volatility.

NWCI在哪个行业运营？

NewCardio operates within the medical device industry, specifically focusing on cardiac diagnostics. The market for non-invasive cardiac monitoring is growing, driven by an aging population and increasing prevalence of cardiovascular diseases. Competition includes established players like BBAL and EVARF, as well as companies focused on specific segments of the cardiac diagnostics market. NewCardio's success depends on its ability to differentiate its technology and secure partnerships with healthcare providers and pharmaceutical companies. The industry is subject to regulatory scrutiny and technological advancements, requiring continuous innovation and adaptation.

Medical - Devices

Healthcare

NWCI有哪些增长机遇？

Expansion of QTinno in pharmaceutical cardiac safety: QTinno, an automated cardiac safety solution, can be expanded within the pharmaceutical industry. The market for cardiac safety assessment during drug development is substantial, driven by regulatory requirements and the need to prevent drug-induced cardiac arrhythmias. Success in this area could generate recurring revenue streams through partnerships with pharmaceutical companies. Timeline: Ongoing.
Commercialization of CardioBip for remote patient monitoring: CardioBip, a mobile ECG transtelephonic system, offers potential for remote patient monitoring, especially for individuals at risk of cardiac events. The market for remote cardiac monitoring is expanding due to the increasing adoption of telehealth and the need for cost-effective healthcare solutions. Successful commercialization of CardioBip could provide a recurring revenue stream through subscription-based services. Timeline: 1-2 years.
Development and launch of my3KG for advanced cardiac analysis: my3KG, a software application to assess cardiac electrical activity in time and space, can provide advanced cardiac analysis, potentially improving diagnostic accuracy. The market for advanced cardiac diagnostics is growing, driven by the need for more precise and personalized treatment strategies. Timeline: 2-3 years.
Strategic partnerships with healthcare providers: Collaborating with hospitals and clinics to integrate NewCardio's diagnostic solutions into their workflows can drive adoption and generate revenue. Strategic partnerships can provide access to a broader patient base and facilitate the integration of NewCardio's technology into existing healthcare systems. Timeline: Ongoing.
Geographic expansion into international markets: Expanding into international markets, particularly in regions with growing healthcare infrastructure and increasing prevalence of cardiovascular diseases, can drive revenue growth. International expansion requires adapting to local regulatory requirements and healthcare practices, but it can provide access to new customer segments and revenue streams. Timeline: 3-5 years.

Gross Margin of 40.8% indicates potential profitability if sales volume increases.
Developing QTinno, an automated cardiac safety solution, addresses a critical need in drug development.
CardioBip mobile ECG system offers a convenient solution for remote cardiac monitoring.
Focus on non-invasive diagnostics aligns with the trend towards less invasive medical procedures.
Proprietary software platform provides a foundation for future product development and innovation.

NWCI提供哪些产品和服务？

Develop proprietary software platform technology solutions for cardiac diagnostics.
Offer non-invasive diagnosis and monitoring of cardiovascular disease (CVD).
Provide cardiac safety assessment of drugs under development.
Offer real-time and 3-D analysis of the heart's electrical activity.
Develop QTinno, an automated cardiac safety solution.
Develop CardioBip, a mobile ECG transtelephonic system.
Develop my3KG, a software application to assess cardiac electrical activity.

NWCI如何赚钱？

Software licensing for QTinno to pharmaceutical companies.
Sales of CardioBip mobile ECG devices.
Subscription-based services for remote cardiac monitoring.
Partnerships with healthcare providers for diagnostic services.

Pharmaceutical companies requiring cardiac safety assessments.
Hospitals and clinics using cardiac diagnostic tools.
Patients requiring remote cardiac monitoring.
Cardiologists and other healthcare professionals.

Proprietary software platform technology.
Patents and intellectual property related to cardiac diagnostic methods.
Expertise in non-invasive cardiac diagnostics.
Established relationships with key opinion leaders in cardiology.

什么因素可能推动NWCI股价上涨？

Upcoming: Regulatory approval of QTinno for automated cardiac safety assessment.
Upcoming: Commercial launch of CardioBip for remote patient monitoring.
Ongoing: Strategic partnerships with pharmaceutical companies for cardiac safety assessments.
Ongoing: Development and launch of my3KG for advanced cardiac analysis.

NWCI的主要风险是什么？

Potential: Dilution of existing shareholders through future equity offerings.
Ongoing: Limited financial resources and potential need for additional funding.
Potential: Competition from larger, more established companies.
Potential: Regulatory setbacks or delays in product approvals.
Ongoing: Dependence on key personnel and potential loss of expertise.

NWCI的核心优势是什么？

Proprietary software platform for cardiac diagnostics.
Focus on non-invasive solutions.
Developing innovative products like QTinno and CardioBip.
Expertise in cardiac safety assessment.

NWCI的劣势是什么？

Limited financial resources.
Small number of employees.
Negative profit margin.
Dependence on successful commercialization of new products.

NWCI有哪些机遇？

Growing market for non-invasive cardiac monitoring.
Increasing demand for cardiac safety assessment in drug development.
Expansion into remote patient monitoring.
Strategic partnerships with healthcare providers and pharmaceutical companies.

NWCI面临哪些威胁？

Competition from established players in the medical device industry.
Regulatory hurdles and approval processes.
Technological obsolescence.
Economic downturn affecting healthcare spending.

NWCI的竞争对手是谁？

Bio-beat Technologies — Focuses on continuous non-invasive monitoring. — (BBAL)
Evara Health — Offers telehealth and remote patient monitoring solutions. — (EVARF)
Future Health — Specializes in personalized medicine and diagnostics. — (FPMI)
Lucid Diagnostics Inc. — Develops diagnostics for esophageal diseases. — (LCDX)
Longport — Offers various medical devices and healthcare solutions. — (LPTI)

Key Metrics

Price: $0.00 (+0.00%)
MoonshotScore: 58/100

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does NewCardio, Inc. (NWCI) do?

NewCardio, Inc. (NWCI) is a cardiac diagnostic and services company that develops and commercializes proprietary software platform technology solutions. The company focuses on non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. Their key products include QTinno, an automated cardiac safety solution, and CardioBip, a mobile ECG transtelephonic system, aiming to improve the accuracy and efficiency of cardiac diagnostics.

Is NWCI stock a good buy?

Evaluating whether NWCI stock is a good buy requires careful consideration. The company's innovative technology in cardiac diagnostics and potential for growth in the remote patient monitoring market are positive factors. However, the negative P/E ratio and significant negative profit margin of -4466.2% indicate financial challenges. Investors should weigh the potential for future revenue growth against the risks associated with a micro-cap company with limited resources and high volatility, as reflected in its beta of -120.60.

What are the risks of investing in NWCI?

Investing in NWCI carries several risks. The company's limited financial resources and negative profit margin raise concerns about its ability to sustain operations and fund future growth. There is a potential risk of dilution through future equity offerings. The company also faces competition from larger, more established players in the medical device industry, as well as regulatory hurdles and potential delays in product approvals. Dependence on key personnel also poses a risk.

What catalysts could move NWCI stock?

Several catalysts could potentially move NWCI stock. Regulatory approval of QTinno for automated cardiac safety assessment would be a significant milestone, as would the commercial launch of CardioBip for remote patient monitoring. Strategic partnerships with pharmaceutical companies for cardiac safety assessments could also drive revenue growth and investor interest. Positive results from the development and launch of my3KG for advanced cardiac analysis could further enhance the company's prospects.

What is NWCI stock price target?

As of March 3, 2026, there is no available analyst consensus or established price target for NWCI stock due to its micro-cap status and limited coverage. Determining a fair value estimate would require a detailed analysis of the company's future revenue potential, profitability, and cash flow projections, considering the inherent risks and uncertainties associated with its stage of development and market position.